Replicate Design [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2014-06-23 15:32 (4018 d 17:26 ago) – Posting: # 13125
Views: 5,410

Hello Naveen,

❝ Please suggest, can we design full replicate bioequivalence study (molecule is highly variable) in stages for EMEA submission.


Yes, that should be a possibility but:
  1. There are no publications about two-stage BE trials combined with replicated designs. You might be asked to prove by your own simulations that type I errors are controlled at max 5% or so.
  2. Don't do it without a meeting with FDA.

❝ My concern is Power will play pivotal role in stage design, which not be in replicate (full) designs.


Not understood - can you explain what you mean?

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,674 registered users;
34 visitors (0 registered, 34 guests [including 19 identified bots]).
Forum time: 08:59 CEST (Europe/Vienna)

I have had my results for a long time:
but I do not yet know how I am to arrive
at them.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5